Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity
- 1 May 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Clinical Nutrition and Metabolic Care
- Vol. 14 (3), 250-254
- https://doi.org/10.1097/mco.0b013e3283455d45
Abstract
Purpose of review A common feature of cancer patients is loss of lean tissue, specifically skeletal muscle, which may be the result of the tumor or a side-effect of chemotherapy or other drugs. Lean tissue loss in turn has important adverse implications for toxicity of antineoplastic therapy and, hence, cancer prognosis. Recent findings Contemporary cancer populations have heterogeneous proportions of lean tissue, regardless of body weight. Wasting of lean tissue during the cancer trajectory has been associated with tumor progression. Lean tissue depletion is an independent predictor of severe toxicity in patients treated with chemotherapeutic agents of diverse classes. Patients with lean tissue depletion behave as if overdosed and have toxicity of sufficient magnitude to require dose reductions, treatment delays or definitive termination of treatment. Muscle loss may occur due to a specific effect of a chemotherapy agent (i.e. sorafenib), androgen suppression therapy or other drugs (i.e. statins such as atorvastatin). Summary Lean tissue wasting occurs due to cancer progression and may be exacerbated by several drug classes. This loss of lean tissue is not proportional to changes in body weight and is prognostic of enhanced treatment toxicity and reduced survival.Keywords
This publication has 24 references indexed in Scilit:
- Muscle Wasting in Cancer Cachexia: Clinical Implications, Diagnosis, and Emerging Treatment StrategiesAnnual Review of Medicine, 2011
- Risk Factors and Drug Interactions Predisposing to Statin-Induced MyopathyDrug Safety, 2010
- Association of Skeletal Muscle Wasting With Treatment With Sorafenib in Patients With Advanced Renal Cell Carcinoma: Results From a Placebo-Controlled StudyJournal of Clinical Oncology, 2010
- Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinomaAnnals Of Oncology, 2010
- Mechanisms of Muscle Atrophy Induced by GlucocorticoidsHormone Research in Paediatrics, 2009
- Metabolic Complications of Androgen Deprivation Therapy for Prostate CancerJournal of Urology, 2009
- A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demandsThe American Journal of Clinical Nutrition, 2009
- Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigationProstate Cancer and Prostatic Diseases, 2008
- Mechanisms of glucocorticoid-induced myopathyJournal of Endocrinology, 2008
- Akt Maintains Cell Size and Survival by Increasing mTOR-dependent Nutrient UptakeMolecular Biology of the Cell, 2002